Macrocyclic inhibitors for the serine protease plasmin

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 24, Issue 3, 2009, Pages 779-794

  Xue, Fengtian ^a   Seto, Christopher T ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Conformational constraint; Inhibition; Macrocyclic; Plasmin; Serine protease

Indexed keywords

3 (1,5 DIOXASPIRO[5.5]UNDECAN 7 YL)PROPANOIC ACID; 5 (2 (TERT BUTOXYCARBONYLAMINO) 3 (1H INDOL 3 YL)PROPANAMIDO)PENTYL 4 METHYLBENZENESULFONATE; 7 (BUT 3 ENYL) 1,5 DIOXASPIRO[5.5]UNDECANE; AMIDE; BENZYL 2 ( 2 (TERT BUTOXYCARBONYLAMINO) 2 CYCLOHEXYLETHANAMIDO) 3 (4 HYDROXYPHENYL)PROPANOATE; BENZYL 2 ( 2 (TERT BUTOXYCARBONYLAMINO) 3 METHYLBUTANAMIDO) 3 (4 HYDROXYPHENYL)PROPANOATE; BENZYL 2 ( 2 (TERT BUTOXYCARBONYLAMINO) 3 METHYLPENTANAMIDO) 3 (4 HYDROXYPHENYL)PROPANOATE; BENZYL 2 ( 2 (TERT BUTOXYCARBONYLAMINO) 3 PHENYLPROPANAMIDO) 3 (4 HYDROXYPHENYL)PROPANOATE; BENZYL 2 ( 2 (TERT BUTOXYCARBONYLAMINO) 4 METHYLPENTANAMIDO) 3 (4 HYDROXYPHENYL)PROPANOATE; BENZYL 2 ( 2 CYCLOHEXYL 2 (5 IODOPENTANAMIDO)ETHANAMIDO 3 (4 HYDROXYPHENYL)PROPANOATE; BENZYL 3 (4 HYDROXYPHENYL) 2 ( 2 (5 IODOPENTANAMIDO) 3 METHYLBUTANAMIDO)PROPANOATE; BENZYL 3 (4 HYDROXYPHENYL) 2 ( 2 (5 IODOPENTANAMIDO) 3 PHENYLPROPANAMIDO)PROPANOATE; BENZYL 3 (4 HYDROXYPHENYL) 2 ( 2 (5 IODOPENTANAMIDO) 4 METHYLPENTANAMIDO)PROPANOATE; BENZYL ALCOHOL ESTER DERIVATIVE; CYCLOHEXANONE; MACROCYCLIC INHIBITOR; PLASMIN; PROTEINASE INHIBITOR; TERT BUTYL 1 (5 HYDROXYPENTYLAMINO) 3 (1H INDOL 3 YL) 1 OXOPROPAN 2 YLCARBAMATE; UNCLASSIFIED DRUG; CYCLOHEXANONE DERIVATIVE; MACROCYCLIC COMPOUND; PEPTIDE; SERINE PROTEINASE INHIBITOR; TRYPTOPHAN; TYROSINE;

ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG BINDING SITE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; THIN LAYER CHROMATOGRAPHY; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHEMICAL MODEL; CHEMISTRY; DRUG DESIGN; ENZYME SPECIFICITY; IC50; METABOLISM; SYNTHESIS;

BINDING SITES; CYCLOHEXANONES; DRUG DESIGN; FIBRINOLYSIN; INHIBITORY CONCENTRATION 50; MACROCYCLIC COMPOUNDS; MODELS, CHEMICAL; PEPTIDES; SERINE PROTEINASE INHIBITORS; SUBSTRATE SPECIFICITY; TRYPTOPHAN; TYROSINE;

EID: 70749157326     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.1080/14756360802364401     Document Type: Article

References (26)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17: 463-516.
2. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-21494.
3. Mignatti P, Rifkin DB. Plasminogen activators and matrix metalloproteinases in angiogenesis. Enzyme Protein 1996;49:117-137.
4. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J. Mechanisms for pro matrix metalloproteinase activation. Acta Pathol Mic Sc 1999;107:38-44.
5. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339: 245-253.
6. Conroy JL, Sanders TC, Seto CT. Using the electrostatic field effect to design a new class of inhibitors for cysteine proteases. J Am Chem Soc 1997;119:4285-4291.
7. Conroy JL, Seto CT. 13C NMR studies demonstrate that tetrahydropyranone- based inhibitors bind to cysteine proteases by reversible formation of a hemithioketal adduct. J Org Chem 1998;63:2367-2370.
8. Abato P, Yuen CM, Cubanski JY, Seto CT. Inhibitors of plasmin that extend into both the S and S0 binding sites: Cooperative interactions between S1 and S2. J Org Chem 2002;67:1184-1191.
9. (d) Abato P, Conroy JL, Seto CT. A combinatorial library of serine and cysteine protease inhibitors that interact with both the S and S0 binding sites. J Med Chem 1999;42:4001-4009.
10. (e) Xue F, Seto CT. A comparison of cyclohexanone and tetrahydro-4H-thiopyran- 4-one 1,1-dioxide as pharmacophores for the design of peptide-based inhibitors of the serine protease plasmin. J Org Chem 2005:70:8309-8321.
11. (f) Xue F, Seto CT. Selective inhibitors of the serine protease plasmin: Probing the S3 and S30 subsites using a combinatorial library. J Med Chem 2005;68:6908-6917.
12. Xue F, Seto CT. Structure-activity studies of cyclic ketone inhibitors of the serine protease plasmin: Design, synthesis and biological activity. Bioorg Med Chem 2006;14:8467-8487.
13. Sanders TC, Seto CT. 4- Heterocyclohexanone-based inhibitors of the serine protease plasmin. J Med Chem 1999;42:2969-2976.
14. Loughlin WA, Tyndall JDA, Glenn MP, Fairlie DP. Beta-strand mimetics. Chem Rev 2004;104:6085-6117.
15. Tyndall JDA, Nall T, Fairlie DP. Proteases universally recognize beta strands in their active sites. Chem Rev 2005;105:973-999.
16. Tyndall JD, Fairlie DP. Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cysteine and metallo proteases. Curr Med Chem 2001;8:893-907.
17. Janetka JW, Raman P, Satyshur K, Flentke GR, Rich DH. Novel cyclic biphenyl ether peptide b-strand mimetics and HIV-protease inhibitors. J Am Chem Soc 1997;119:441-442.
18. Reid RC, March DR, Dooley MJ, BergmanDA, Abbenante G, Fairlie DP. A novel bicyclic enzyme inhibitor as a consensus peptido-mimetic for the receptor-bound conformations of twelve peptidic inhibitors of HIV-1 protease. J Am Chem Soc 1996;118:8511-8517.
19. Chen KX, Njoroge FG, Pichardo J, Prongay A, Butkiewicz N, Yao N, Madison V, Girijavallabhan V. Potent 7-hydroxy- 1,2,3,4-tetrahydroisoquinoline-3- carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem 2006;49:567-574. (Pubitemid 43158440)
20. Tsantrizos YS, Ferland J-M, McClory A, Poirier M, Farina V, Yee NK, Wang X, Haddad N, Wei X, Xu J, Zhang L. Olefin ring-closing metathesis as a powerful tool in drug discovery and development - potent macrocyclic inhibitors of the hepatitis C virus NS3 protease. J Organomet Chem 2006;691: 5163-5171.
21. Meyer JH, Bartlett PA. Macrocyclic inhibitors of penicillopepsin 1. Design, synthesis, and evaluation of an inhibitor bridged between P1 and P3. J Am Chem Soc 1998;120: 4600-4609.
22. Stachel SJ, Coburn CA, Sankaranarayanan S, Price EA, Pietrak BL, Huang Q, Lineberger J, Espeseth AS, Jin X, Elis J, Holloway MK, Munshi S, Allison T, Hazuda D, Simon AJ, Graham SL, Vacca JP. Macrocyclic inhibitors of b-secretase: Functional activity in an animal model. J Med Chem 2006;49: 6147-6150.
23. Xue CB, Voss ME, Nelson DJ, Duan JJ, Cherney RJ, Jacobson IC, He X, Roderick J, Chen L, Corbett RL, Wang L, Meyer DT, Kennedy K, DeGradodagger WF, Hardman KD, Teleha CA, Jaffee BD, Liu RQ, Copeland RA, Covington MB, Christ DD, Trzaskos JM, Newton RC, Magolda RL, Wexler RR, Decicco CP. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor a release in vitro and in vivo. J Med Chem 2001;44:2636-2660.
24. Thaisrivongs S, Pals DT, Turner SR, Kroll LT. Conformationally constrained renin inhibitory peptides: G-lactambridged dipeptide isostere as conformational restriction. J Med Chem 1988;31:1369-1376.
25. Okada Y, Tsuda Y, Teno N, Wanaka K, Bohgaki M, Hijikata-Okunomiya A, Naito T, Okamoto S. Synthesis of active center-directed peptide inhibitors of plasmin. Chem Pharm Bull 1988;36:1289-1297.
26. Okamoto S, Sato S, Tanaka Y, Okamoto U. An active stereoisomer (trans form) of AMCHA and its antifibrinolytic (antiplasminic) action in vitro and in vivo. Keio J Med 1964;13:177-185.